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ABSTRACT: Chemotherapy-induced hemorrhagic cystitis (CHC) can be difficult to manage. Prior work suggests that
IL-4 alleviates ifosfamide-induced hemorrhagic cystitis (IHC), but systemically administered IL-4 causes signifi-
cant side effects. We hypothesized that the Schistosoma hematobium homolog of IL-4-inducing principle from
Schistosoma mansoni eggs (H-IPSE), would reduce IHC and associated bladder pathology. IPSE binds IgE on
basophils andmast cells, triggering IL-4 secretionby thesecells. IPSE is also an “infiltrin,” translocating into thehost
nucleus to modulate gene transcription. Mice were administered IL-4, H-IPSE protein or its nuclear localization
sequence (NLS) mutant, with or without neutralizing anti-IL-4 antibody, or 2-mercaptoethane sulfonate sodium
(MESNA; a drug used to prevent IHC), followed by ifosfamide. Bladder tissue damage and hemoglobin content
were measured. Spontaneous and evoked pain, urinary frequency, and bladdergene expression analysis were
assessed. Pain behaviors were interpreted in a blinded fashion. One dose of H-IPSE was superior to MESNA and
IL-4 in suppressingbladder hemorrhage in an IL-4-dependent fashion and comparablewithMESNAindampening
ifosfamide-triggered pain behaviors in an NLS-dependent manner. H-IPSE also accelerated urothelial repair fol-
lowing IHC. Our work represents the first therapeutic exploitation of a uropathogen-derived host modulatory
molecule in a clinically relevant bladder diseasemodel and indicates that IPSEmaybe analternative toMESNA for
mitigatingCHC.—Mbanefo, E.C., Le, L., Pennington,L. F.,Odegaard, J. I., Jardetzky,T.S.,Alouffi,A., Falcone,F.H.,
Hsieh, M. H. Therapeutic exploitation of IPSE, a urogenital parasite-derived host modulatory protein, for
chemotherapy-induced hemorrhagic cystitis. FASEB J. 32, 4408–4419 (2018). www.fasebj.org
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Hemorrhagic cystitis can result as a pathogenic feature of
infection, radiation therapy, and chemotherapy. Themost
common inciting agents for the latter are cyclophospha-
mide and ifosfamide, nitrogen mustard alkylating agents
used to treat many cancers (1). Liver metabolism of cy-
clophosphamide and ifosfamidegenerates acrolein,which
concentrates in the urine, activating cascades that can lead
to hemorrhagic cystitis (2). Indeed, toxicity in the form of
hemorrhagic cystitis can be a dose-limiting factor for these
drugs (3). Up to 40% of patients receiving cyclophospha-
mide and ifosfamide experience some degree of hemor-
rhagic cystitis (4), which can result in major chronic
sequelae, such as hematuria, urinary frequency, strangu-
ria, small volume voids, bladder spasms, reduced bladder
capacity, and increased risk of development of second-
ary bladder cancer. 2-Mercaptoethane sulfonate sodium
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(MESNA) is given to prevent cyclophosphamide- and
ifosfamide-associated hemorrhagic cystitis. This drug
works by scavenging acrolein, a highly reactive nucle-
ophile metabolite of ifosfamide, which concentrates in
bladder urine and causes tissue damage. However,
MESNA fails to treat established hemorrhagic cystitis
(5, 6). Moreover, its use can result in systemic hyper-
sensitivity reactions, including arrhythmias (7). In
studies of MESNA- and ifosfamide-exposed bladders,
cystoscopy and histology show that two-thirds and
100% of patients, respectively, still have evidence of
significant bladder injury despite MESNA prophylaxis
(8). Options for MESNA-refractory, cyclophosphamide-
induced hemorrhagic cystitis and ifosfamide-induced
hemorrhagic cystitis (IHC) are limited and suboptimal (9).
Cytokines, particularly IL-4, appear to play an impor-
tant role in chemotherapy-induced hemorrhagic cysti-
tis (CHC) and thus, are promising therapeutic strategies.
Administration of recombinant IL-4 alleviates IHC via
attenuation of bladder TNF-a, IL-1b, iNOS, and cyclo-
oxygenase 2 (COX-2) (10), which are proinflammatory
mediators previously associatedwith hemorrhagic cystitis
(2, 11–16). Interestingly, exposure of mice to ifosfamide
induces endogenous IL-4 production, suggesting that
there are intrinsic, IL-4-related homeostatic responses to
this chemotherapeutic agent (10). Accordingly, both anti-
body- and transgenic-based abrogation of IL-4 activity in
mice results in more severe IHC (10). However, systemic
administration of IL-4 is unlikely to be an acceptable pro-
phylactic or therapeutic approach for cyclophosphamide-
induced hemorrhagic cystitis and IHC. For instance,
clinical trials of systemic administration of IL-4 for cancer
therapy have resulted in untoward side effects (17–28).
Nevertheless, evidence suggests that IL-4-associated anti-
inflammatory pathways and targets thereof are promising
therapeutic candidates for hemorrhagic cystitis.
The Schistosoma hematobium homolog of IL-4-inducing
principle from Schistosoma mansoni eggs (H-IPSE) is a
molecule that may modulate S. hematobium-associated
hemorrhagic cystitis and broader host bladder biology.
Like ifosfamide,S. hematobium infection is associatedwith a
form of hemorrhagic cystitis, thought to be chiefly caused
by chronic inflammation induced by eggs deposited in the
bladder wall and by passage of eggs through the bladder
and into the urinary stream. IPSE is the most abundant
parasite egg-secreted protein, and no homolog exists out-
side of the genus Schistosoma (29). Chronic S. hematobium
infection, but not S. mansoni infection, is associated with
hematuria. However, only a minority of infected individ-
uals shows day-to-day hematuria or other urinary symp-
toms (30). Whereas other factors, including intensity of
infection, are associated with the degree of hematuria, it is
possible that a parasite molecule-induced modulatory ef-
fectmayplaya role in thispathogenesis.Thus,wereasoned
that H-IPSE may have evolved as species-specific mole-
cules responsible for carefully calibratinghosthemorrhagic
cystitis, which in controlled degrees, may be necessary for
egg passage but is detrimental to host (and thus, parasite)
when excessivemorbidity results (31). S. mansoni IPSE (M-
IPSE) binds Igs, in particular, IgE, on basophils and mast
cells, which triggers IL-4 secretion (32–34). M-IPSE also
sequesters chemokines (35) and is an infiltrin that reliesona
nuclear localization sequence (NLS) to enter host cell nuclei
to alter gene transcription (36, 37). We hypothesized that
similar IL-4-inducing and NLS-dependent functions exist
in H-IPSE (38), and that these properties may alleviate
IHC. Indeed, we found that a single intravenous dose of
H-IPSE was superior to MESNA and IL-4 in suppressing
ifosfamide-induced bladder hemorrhage in mice and sim-
ilar in efficacy to these agents in its ability to dampen
ifosfamide-induced pain and abnormal voiding patterns.
These features were variably IL-4 and NLS dependent.
MATERIALS AND METHODS
Study approval
All animal work has been conducted according to relevant U.S.
and international guidelines. Specifically, animal experimental
protocols were reviewed and approved by the Institutional An-
imal Care and Use Committee of the Biomedical Research In-
stitute (Rockville, MD, USA). Our Institutional Animal Care and
Use Committee guidelines comply with the U.S. Public Health
Service Policy onHumane Care andUse of LaboratoryAnimals.
Animals, reagents, and drugs
Female 6- to 8-wk-old C57BL/6 mice (Charles River Laborato-
ries, Wilmington, MA, USA) and IL-4/green fluorescent protein
(GFP)-enhanced transcript (4get) mice (39) (The Jackson Labo-
ratories, Bar Harbor, ME, USA) were housed under 12 h light-
dark cycles in temperature-controlled holding rooms with
unlimited access to dry mouse chow and water. Our group has
cloned and characterized different variants of H-IPSE (38). Ifos-
famide and MESNA (both .98% purity) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Recombinant murine IL-4
was obtained from Peprotech Laboratories (Rocky Hill, NJ,
USA). Neutralizing anti-IL-4 mAb (11B11 clone) was purchased
from BioXcell (West Lebanon, NH, USA).
Recombinant protein preparation
Themethodused forH-IPSE identification, generation of itsNLS
mutant, cloning, andexpressionwaspreviouslydescribedbyour
group (38). Material for in vitro and in vivo experiments un-
derwent the following expression and purification protocol. One
milligram of plasmid DNA was purified using a GenElute HP
endotoxin-free plasmid Maxiprep kit (Sigma-Aldrich) and was
incubated with 3 mg linear 25 kDa polyethylenimine (Poly-
Sciences, Warrington, PA, USA) at 1 mg/ml, diluted in 10 ml
sterile PBS, pH 7.4, for each 1 L transfection. Secreted recombi-
nant protein was expressed in human embryonic kidney 293-6E
cells (40) for 5 d in suspension culture using FreeStyle 293 me-
dium (Thermo Fisher Scientific, Waltham, MA, USA) and puri-
fied over 10mlNi-NTA resin (Qiagen, Germantown,MD,USA),
equilibrated with 10 mM imidazole PBS, pH 7.4, washed with 5
resin bed volumes of 25 mM imidazole PBS, pH 7.4, and eluted
with 300 mM imidazole PBS, pH 7.4. The eluted protein was
concentrated with a 10 kDa cutoff 15 ml Amicon Ultra Centrif-
ugal Filter Unit (EMD Millipore, Billerica, MA, USA) to a con-
centration of no .0.5 mg/ml and purified on a Hiload 16/600
Superdex 200 Column (GE Healthcare, Waukesha, WI, USA).
Before purification, FPLC machines and Hiload columns were
cleanedwith 0.5MNaOHfor 1.5 columnvolumes at a flow rate of
1ml/min (3 h) and thenwashedwith 1.5 columnvolumes of PBS,
pH 7.4. All buffers were made with MilliQ ddH2O to reduce
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pyrogen contamination, and mutant protein controls were puri-
fied on the same day with identical buffers. All protein samples
were further filter sterilizedbypassage througha0.22-mmsyringe
filter.
Hemorrhagic cystitis model
The IHC model used in this study was adapted from methods
previously described by Macedo et al. (10). Mice were: 1) in-
travenously injected with 25 mg H06 H-IPSE or the NLS mutant
of H-IPSE, 24 h before intraperitoneal ifosfamide injection
(400 mg/kg); 2) injected with H-IPSE, followed 23.5 h later by
intraperitoneal injectionof100mgneutralizinganti-IL-4antibody
(11B11), given 30 min before ifosfamide injection; 3) intraperito-
neally administered 10 ng recombinant IL-4, 1 h before ifosfa-
mide injection; 4) given MESNA [80 mg/kg, 20% of ifosfamide
dose (10)] just before ifosfamide injection and 2 more doses, 4 h
apart; 5) intraperitoneally administered saline alone; or 6) in-
jectedwith saline, followedby ifosfamide (400mg/kg), 24h later.
Mice were monitored for 12-h postifosfamide injection, before
they were euthanized for downstream experiments.
Gross evaluation of bladders for edema
and hemorrhage
Mice were euthanized 12 h postifosfamide injection and their
bladders immediately excised, weighed to measure bladder wet
weight, and used for downstream experiments. Bladders were
also evaluated macroscopically for signs of edema and hemor-
rhageonascaleof 0– 3+, followingGray’s scoringcriteria (41) and
aspreviouslydetailed (10).Forhemorrhage,normalwasscoredas
0, dilation of blood vesselswas scored as 1+,mucosal hematomas
were scored as 2+, and intravesical clots were scored as 3+.
Bladder histology
Bladders were fixed in 10% neutral-buffered formalin and
later dehydrated and embedded in paraffin. Paraffin-embedded
bladders were cut into 5-mm sections and then processed for
hematoxylin and eosin staining. The stained sections were eval-
uated microscopically (in a blinded fashion by J.I.O.) for the
presence of urothelial denudation, lamina propria edema, hem-
orrhage, and cellular infiltration.
Measurement of bladder hemoglobin
concentration using Drabkin’s reagent
Drabkin’s assay is a cyanomethemoglobin-basedmethod toassess
thehemoglobin content of tissue (bladder) as anobjectivemeasure
of hemorrhage. The assay was performed according to the man-
ufacturer’s instructions (Sigma-Aldrich) and adapted from Mac-
edo et al. (10). In brief, we homogenized whole bladders in
Drabkin’s reagent (100 mg tissue/ml reagent), and the homoge-
nates were centrifuged at 10,000 g for 10 min. The supernatants
were centrifuged a second time at 10,000 g for 10 min to ensure
complete clearance of debris. Absorbance was then measured at
540 nm on a plate reader. A standard curve for the estimation of
hemoglobin content was generated using known amounts of he-
moglobin (Cayman Chemical, Ann Arbor, MI, USA).
Spontaneous pain evaluation
Spontaneous pain behaviors were scored using previously pub-
lishedmethods (42–45), asdetailedbyLeventhal andStrassle (46)
and as adapted in our laboratory. In brief, mice were placed
individually in fresh cages with new bedding. After acclimatiz-
ing for 30 min, mice were evaluated for spontaneous pain char-
acteristics. The spontaneouspain characteristicswere scored (in a
blinded fashion) by observing the mouse for 1 min for any of
these characteristics: normal = 0; piloerection (ruffled fur) = 1;
labored breathing = 2; ptosis (drooping of upper eyelid) = 3;
Licking of abdomen (not grooming) = 4; rounded back = 5. The
sumof any observed behaviors/appearance for eachmousewas
used as the overall spontaneous pain score.
Evoked pain evaluation (von Frey monofilament
assessment of tactile allodynia)
Evokedpainwas estimated in a blinded fashion using von Frey’s
monofilamentswith the following range of bending forces: 0.008,
0.04, 0.16, 0.4, 0.6, 1.0, 1.4, and 2 g. We adopted the up-down
method by Chaplan et al. (47), as detailed by Leventhal and
Strassle (46) and adapted in our laboratory.Mice were placed on
wiremesh in an apparatus constructed using an invertedmouse
cage and left to acclimatize for 30min. Fromunderneath the cage
through the wire mesh, the tip of a 0.4 g von Frey monofilament
was applied to thehindpawuntil the filament bent and thenheld
for up to 5 s. Responses include rapid withdrawal, jumping, or
lickingof thestimulatedspot. Ifnoresponsewasobserved, thenext-
higher force fiber was applied until a withdrawal response was
observed or until 2-g cutoff was reached. If a withdrawal occurred
at the initial stimulation using the 0.4 g force fiber, then the next-
lighter forcewas applieduntil a bending force of 0.008g (minimum
cutoff) was reached. Subsequently, whenever a response was ob-
served, we continued to a lighter fiber, and if no response was
observed, we continued to a stronger fiber, until at least 6 unique
withdrawal evaluations were obtained. The 50% withdrawal
threshold was calculated using the equation [10(Xf + kd)/10,000],
where the k value of the response pattern was determined accord-
ing toDixon (48) andasdescribedbyLeventhal andStrassle (46);Xf
represents the logunits value for the last vonFrey filament applied.
For the set ofmonofilamentsused in this study,d—standing for the
mean difference between stimuli—was 0.285.
Void spot on a paper assay
The voided spot on paper assay formeasuring voiding frequency
andvoidingpatternswasperformed, as previouslydescribed (49,
50) and according to our own published experience (51, 52). In
short, a piece of Whatman No. 1 filter paper was cut to cover the
entire bottom surface of a mouse cage. Wire mesh was used to
preventmouse access to the filter paper. Individualmicewere left
in covered cages with only mouse chow provided. After 4 h, the
filter papers were recovered and the urine spots detected by UV
transillumination. A standard curve for estimation of urine vol-
umewas generated by preparation of filter paperwith controlled
drops of known, increasing volumes of mouse urine.
Gene expression analysis by real-time PCR
Bladders were aseptically excised and immediately placed in
RNAzol solution in a tube containing zirconium beads for sub-
sequent homogenization of bladder tissues. Total RNA was pu-
rifiedusing theRNAzolmethod, according to themanufacturer’s
instructions. With the use of the same concentration of total
RNA for all samples (500 ng), cDNA was synthesized using the
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Real-
time PCR was performed using the iTaq universal SYBR Green
Supermix, following the manufacturer’s protocols. The primers
used for real-time PCR are as follows: uroplakin 1a (Up1a;
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59-TACACCCACCGCGACTATATG-39 and 59-CCACAACACT-
CTTGCTCAATCAT-39),Up2 (59-TGCCCCTGATCCTGATTCTG-
39 and 59-CAAGGCAATTAACAGGCTTTCTG-39), claudin 8
(Cldn8; 59-AGAGCCGCATCTTGCTGAC-39 and 59-TCTGATG-
ATGGAATTGGCAACC-39), Il-1b (59-GAAATGCCACCTTTTG-
ACAGTG-39 and 59-TGGATGCTCTCATCAGGACAG-39), Tnf-a
(59-GTGGAACTGGCAGAAGAG-39 and 59-CCATAGAACTG-
ATGAGAGG-39), iNOS (59-ACATCGACC-CGTCCACAGTAT-39
and 59-CAGAGGGGTAGGCTTGTCTC-39), Il-8 (59-CACCT-
CAAGAACATCCAGAGCT-39 and 59-CAAGCAGAACTGAA-
CTACCATCG-39), Ccl3 (59-CAGCCAGGTGTCATTTTCCT-39 and
59-CTGGCTCCAAGACTCTCAGG-39), Cox-2 (59-CAAGGGAGT-
CTGGAACATTG-39 and 59-ACCCAGGTCCTCGCTTATGA-39),
and glyceraldehyde 3-phosphate dehydrogenase (59-AGGTC-GGTG-
TGAACGGATTTG-39 and 59-TGTAGACCAT-GTAGT-TGAG-
GTCA-39). Relativegene expressionwas thenanalyzedusing the
comparative threshold (Ct) method with fold expression using
the formula 2(2ΔΔCt), with glyceraldehyde 3-phosphate de-
hydrogenase as the internal reference and the saline-only group
as the baseline negative control.
Flow cytometry
Flow cytometry was performed on peripheral blood leukocytes
and cells from dissociated bladder tissues from 4get mice to eval-
uate IL-4 expression, 24 h after intravenous injection of H-IPSE or
PBS. In brief, whole blood was collected from 4get mice, followed
by red blood cell (RBC) lysis for 10 min using RBC lysis buffer
(150mMNH4Cl, 10mMKHCO3, 0.1mMNa2 EDTA, pH7.2–7.4).
Freshly excised bladders were dissociated in tissue-dissociated
solution following our previously described method (52), before
RBC lysis. The cells were filtered through a 40 mm mesh, and
resulting single-cell suspension was counted, and then 106 cells
were washed twice using flow cytometry wash buffer (1 time PBS
containing 0.02% sodium azide, 1% bovine serum albumin) and
blocked using 5 ml (0.5 mg/ml) mouse Fc-blocking antibody (anti-
CD16/CD32 mAb) for 30 min at 4°C. The cells were then stained
with combinations of anti-CD3-PE-Cy7, anti-CD49b-eFluor, and
anti-c-kit-allophycocyaninmAbforbasophilandmastcell estimation
andanti-CD45-allophycocyanin andanti-Ly6G-Pacific BluemAb for
neutrophil detection and then incubated on ice in the dark for 1 h.
The stained cells were washed twice, resuspended in 1 ml flow
cytometry wash buffer, and acquired on a BD FACSCanto II ma-
chine (BD Biosciences San Jose, CA, USA). Flow cytometric anal-
yses were performed using the FlowJo fluorescence-activated cell
sorting analysis platform, version 10.1 (FlowJo, Ashland, OR,
USA). IL-4 expression was assessed using the FITC channel to
detect IL-4-linked GFP expression by 4get mice.
Statistics
Data analysis was performed on GraphPad Prism (GraphPad
Software, La Jolla, CA, USA), v.6.00. For comparison within
groups, 1-wayANOVAwasperformed, and if significant,post hoc
Student’s t testswere then used to performpairwise comparisons
after confirminganormaldistributionof thedata.All plotteddata
are individual data points, with error bars representing means6
SD. Statistical significance was designated as P, 0.05.
RESULTS
H-IPSE (variant H06) induces basophils to
release IL-4
Others have previously reported that M-IPSE binds to IgE,
present on FcRs on the surface of basophils and mast
cells, thereby inducing IL-4 secretion (53). We used IL-4
transcription-linked GFP expression in 4get mice (39) to
confirm that a single intravenous injection of theH06variant
of H-IPSE induces IL-4 transcription in basophils. Supple-
mentalFig. 1showsarepresentative flowcytometricanalysis
gating strategy for CD32IL-4+CD49b+ cells, including baso-
phils (SupplementalFig.1).CD32IL-4+c-kit+expressionwas
used to identify mast cells. BALB/c-negative controls
showed no GFP-linked IL-4 expression. IL-4-linked GFP
expression was consistently detectable in all 4get mice
groups assessed (Fig. 1). There was a statistically signifi-
cant increase (P = 0.0394) in IL-4-positive basophils in
peripheral blood (Fig. 1A) but not mast cells (Fig. 1B) from
4getmice intravenously injectedwithH06H-IPSEcompared
with 4get mice receiving PBS. This difference was not ob-
served in cells collected from the bladder (Fig. 1C, D). After
ifosfamide challenge, the proportion of IL-4-expressing cells
in thebladderwas increased in bothH-IPSEandPBSgroups
compared with ifosfamide-naive mice. However, there
was no difference in the proportion of IL-4-positive
basophils and mast cells between the H-IPSE- and PBS-
exposed groups after ifosfamide injection.
H-IPSE reduces ifosfamide-induced bladder
hemorrhage and hemoglobin content, but
not bladder wet weight and edema, in an
IL-4- and NLS-dependent manner
Having demonstrated that H06 H-IPSE shares several
features with M-IPSE, including activating IgE-bearing
basophils to produce IL-4 and localizing in host cell
nuclei (38), we next sought to determine any in vivo
effects of H06 H-IPSE in the ifosfamide-induced mouse
model of hemorrhagic cystitis. Mice were given saline
alone or ifosfamide in combination with the following:
1) an intravenous injection ofH06H-IPSE (wild-type) or
anH-IPSEmutant lacking the NLS; 2) H06H-IPSE or its
NLS mutant, followed by neutralizing anti-IL-4 anti-
body; 3) recombinant IL-4; 4) MESNA; or 5) saline.
Compared with mice administered only saline before
ifosfamide, mice given H06 H-IPSE showed a signifi-
cant reduction (42.3%, P = 0.0008) in macroscopically
apparent bladder hemorrhage. This H-IPSE-mediated
reduction in bladder hemorrhage was comparable with
the MESNA (42.9%, P = 0.0096) and IL-4 (35.3%, P =
0.0005) treatment groups (Table 1). The observed H06
H-IPSE-mediated reduction in bladder hemorrhage
was reversedwhen neutralizing anti-IL-4 antibodywas
administered before ifosfamide injection and reduced
when the NLS mutant of H-IPSE was given (albeit not
statistically significant). Likewise, bladder hemoglobin
content was significantly reduced in the H-IPSE-
injected group compared with the ifosfamide-only
group (P = 0.0133; Fig. 2A). Indeed, H-IPSE decreased
ifosfamide-induced bladder hemoglobin content better
than MESNA and IL-4. This effect of H-IPSE was re-
versed when neutralizing anti-IL-4 antibody was ad-
ministered after H-IPSE injection, but the difference
was not statistically significant (Fig. 2A). Furthermore,
relative to the H-IPSE-injected group and although not
achieving statistical significance, bladder hemoglobin
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content was higher in mice given the NLS mutant of H-
IPSE. When neutralizing anti-IL-4 antibody was
administered to the NLS mutant H-IPSE group, the
hemoglobin content was further significantly increased
(P = 0.002; Fig. 2A). Although we noted a decrease in
bladder-infiltrating neutrophils in the H06 H-IPSE-
treated group compared with the PBS-treated group
after ifosfamide injection (Supplemental Fig. 2), all mice
receiving ifosfamide, with or without treatments,
showed increased bladder wet weight and edema
compared with mice not given ifosfamide (Fig. 2B
and Table 1). Furthermore, compared with the group
receiving only saline before ifosfamide, a signifi-
cant reduction in bladder edema was only observed in
mice given MESNA in combination with ifosfamide
(P = 0.0409).
TABLE 1. H-IPSE reduces bladder hemorrhage in ifosfamide-treated mice
Hemorrhage Edema
Experimental group Mean 6 SEM % Reduction P Mean 6 SEM % Reduction P
Saline 0.143 6 0.078 93.3 ,0.0001 0.048 6 0.048 96.9 ,0.0001
Ifosfamide 2.125 6 0.151 ref ref 1.542 6 0.241 Ref ref
IL-4 + ifosfamide 1.375 6 0.132 35.3 0.0005 1.167 6 0.253 24.3 ns
H-IPSEH06 + ifosfamide 1.227 6 0.197 42.3 0.0008 1.273 6 0.220 17.4 ns
H-IPSEH06 + anti-IL-4 antibody +
ifosfamide
2.0 6 0.258 5.9 ns 2.0 6 0.394 229.7 ns
H-IPSENLS + ifosfamide 1.700 6 0.213 20 ns 1.200 6 0.359 22.2 ns
H-IPSENLS + anti-IL-4 antibody +
ifosfamide
2.0 6 0.577 5.9 ns 1.0 6 0.408 35.1 ns
MESNA + ifosfamide 1.214 6 0.281 42.9 0.0096 0.786 6 0.261 49.0 0.0409
Ns, not signiﬁcant; ref, reference group.
Figure 1. Intravenous injection of H-IPSE
induces IL-4 expression by basophils. A) A
higher proportion of basophils from the
peripheral blood of H-IPSE-injected mice were
IL-4+ compared with PBS-injected mice. After
ifosfamide (Ifos) injection, this cell population
was similar in both H-IPSE and PBS groups. B)
There was no signiﬁcant difference in IL-4+
peripheral blood mast cells between H-IPSE
and PBS groups before and after ifosfamide
injection. C) IL-4-expressing basophils were
present at higher numbers in the bladders of
both H-IPSE and PBS groups after ifosfamide
injection. D) There was no difference in IL-4-
positive bladder mast cells, with or without
ifosfamide, between the H-IPSE and PBS
groups. Consistently, BALB/c mice did not
express GFP (IL-4), as expected. Plotted data
are pooled from 2 repeat experiments (n =
3–7). Horizontal bars represent means. *P ,
0.05, **P , 0.01, ***P , 0.001.
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H-IPSE reduces IL-4-dependent, histologically
evident pathologic changes in the
ifosfamide-exposed bladders
The bladders of mice treated with saline, H-IPSE, H-IPSE
followed by neutralizing anti-IL-4 antibody, recombinant
IL-4, orMESNAwere subjected tohistologic analyses, 12h
after ifosfamide injection. Compared with the bladder
sections from mice given only saline and no ifosfamide
(Fig. 3A), we observed histologic evidence of urothelial
denudation, lamina propria edema, and hemorrhage in
the group of mice treated with only saline before ifosfa-
mide (Fig. 3B). Conversely, groups of mice treated with
MESNA (Fig. 3C) or IL-4 (Fig. 3D), as well as the H-IPSE-
treated group (Fig. 3E), all showed significantly reduced
bladder pathology, including more intact urothelium and
decreased edema and hemorrhage. However, it was ap-
parent that anti-IL-4 antibody reversed the protective ef-
fect of H-IPSE (Fig. 3F), as significant bladder pathology
was observed in mice given both H-IPSE and anti-IL-4
antibody, akin to the ifosfamide-only group.
H-IPSE attenuates spontaneous and evoked
pain responses in ifosfamide-injected mice
To determine whether H-IPSE also ameliorates CHC-
associated pain, mice were evaluated for spontaneous
pain characteristics, as well as von Frey monofilament-
based evaluation of evoked pain. Whereas spontaneous
pain was induced in all mice receiving ifosfamide, spon-
taneous pain scores were significantly reduced in the
groups of mice injected with H-IPSE (P = 0.0007) and
MESNA (P = 0.0016) compared with the mice receiving
only ifosfamide (Fig. 4A). Interestingly, the therapeutic
effect ofH-IPSEwasabsentor reduced in thegroupofmice
given the NLS mutant of H-IPSE (P = 0.0161). Adminis-
tration of neutralizing anti-IL-4 antibody did not reverse
this protective effect of H-IPSE. Evaluations of allodynia
(evoked pain responses) demonstrated that changes in
withdrawal threshold observed for the H-IPSE and IL-4
groups were like the negative-control (saline-only, no
ifosfamide) group but not statistically different from the
ifosfamide-only and the H-IPSE NLS-mutant groups.
However, the effect of H-IPSE on evoked pain was sig-
nificantly reversed when neutralizing anti-IL-4 antibody
was administered in addition toH-IPSEor itsNLS-mutant
(Fig. 4B).
Effect of H-IPSE on voiding patterns in
ifosfamide-exposed mice
To determine the effect of H-IPSE injection on ifosfamide-
induced abnormal voiding behaviors, changes in voiding
frequency and voiding pattern were assessed through
application of the voided spot assay on ifosfamide-
exposedmice. Generally, the voiding patterns in the H-IPSE
and MESNA-treated groups resembled the saline only neg-
ative control-treated group (Fig. 5, Supplemental Figs. 3 and
4). Voiding frequency was significantly increased in the ifos-
famide-injected group relative to the saline only negative
control group (P5 0.0132), H-IPSE-treated (P5 0.0406), and
MESNA-treated (P 5 0.0037) groups, respectively (Fig. 5).
While the voiding frequency of mice administered neutral-
izing anti-IL-4 antibody after H-IPSE resembled that of mice
given ifosfamidealone, administrationof recombinant IL-4 to
ifosfamide-exposedmice did not affect voiding frequency.
H-IPSE restores normal gene expression
of urothelial differentiation markers in
ifosfamide-injured bladders in an
IL-4- and NLS-dependent manner
Uroplakins are urothelial-specific transmembrane pro-
teins that function to maintain urinary-tract integrity and
are markers of urothelial differentiation. It has been pro-
posed that uroplakins may be the primary molecular tar-
get of ifosfamide/cyclophosphamide-induced acrolein
Figure 2. H-IPSE reduces blad-
der hemoglobin levels, but not
bladder wet weight, in ifosfa-
mide-treated mice. A) Mice
were administered recombinant
IL-4, H-IPSE, and the NLS
mutant of H-IPSE, with or with-
out neutralizing anti-IL-4 anti-
body (a-IL4), MESNA, or saline,
before ifosfamide challenge. An-
imals were then euthanized and
their bladders excised, weighed
to measure bladder wet weight,
and then subjected to the Drab-
kin’s test to measure tissue
hemoglobin levels. The H-IPSE-
treated group showed signiﬁcantly
reduced bladder hemoglobin
levels compared with the ifosfamide-only group, and prior administration of neutralizing anti-IL-4 antibody reversed the effect
of H-IPSE, albeit without achieving statistical signiﬁcance. The NLS mutant-treated group, as well as MESNA-treated mice, did not
exhibit a signiﬁcant decrease in bladder hemoglobin following ifosfamide exposure. Plotted data are pooled from 3 repeat
experiments (n = 3–4 each). The bars represent means and SD. B) There were no signiﬁcant differences in bladder wet weights
across treatment groups. Horizontal bars represent means. *P , 0.05, **P , 0.01.
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and reactive oxygen species in the bladder (54). We
measured levels of uroplakin as readout for urothelial
denudation and surrogate for urothelial regeneration. In-
deed, we observed significant decreases in bladder ex-
pression of theuroplakin genesUp1a (P= 0.0030) andUp2
(P = 0.0174) in mice injected with ifosfamide, 12 h earlier,
compared with mice given 1 intravenous dose of H-IPSE
before ifosfamide (Fig. 6A, B). In line with a previous re-
port that MESNA preserves urothelial integrity and uro-
plakin expression (55), we also found significantly higher
expression of Up1a (P , 0.0001) and Up2 (P = 0.0001) in
mice injected with 3 doses of MESNA at 0, 4, and 8 h
postifosfamide exposure compared with the mice given
saline before ifosfamide. Administration of the anti-IL-4
antibody to H-IPSE-injected mice before ifosfamide insult
significantly reversed the protective effect of H-IPSE on
Up1a (P = 0.0027) and Up2 (P = 0.0143) expression com-
pared with the H-IPSE-treated group. Although the NLS
mutant-treated group featured lower expression of Up1a
compared with the wild-type H-IPSE-treated group
(P = 0.0167), the NLS mutant of H-IPSE induced higher
expression of bothUp1a (P = 0.0022) andUp2 (P = 0.0007)
compared with the mice given saline before ifosfamide
(Fig. 6A,B).Aspreviously reported, thenatural urothelial-
regenerative response after bladder insult sets in 12 h
postchallenge (56, 57). This may explain why the ex-
pression of uroplakinswas almost restored to baseline in
the ifosfamide-only group, but the rate of such increase
was significantly higher in theH-IPSE,MESNA, and IL-4
groups. In line with previous observations by Golubeva
et al. (58), gene expression of the tight junction pro-
tein Cldn8 (Fig. 6C) was neither significantly affected by
H-IPSE injection nor ifosfamide exposure.
H-IPSE affects gene expression of iNOS, but
not IL-1b and TNF-a, in ifosfamide-exposed
bladders in an IL-4- and NLS-
independent fashion
The pathogenesis of CHC is mediated by the activities of
soluble mediators, including proinflammatory cytokines,
such as Il-1b andTnf-a, NOproduction through the action
of iNOS, prostaglandin production by Cox-2 (2, 11–16),
and chemokines. We assessed the effect of H-IPSE
on the expression of representative proinflammatory
mediators in ifosfamide-injected mice. All treatment
Figure 3. H-IPSE mitigates ifos-
famide-induced histopathologi-
cal changes in the bladder.
Histologic assessment of blad-
ders from mice receiving the
following: saline only (A), ifos-
famide only (B), MESNA and
ifosfamide (C), recombinant
IL-4 and ifosfamide (D), H-IPSE
and ifosfamide (E ), and
H-IPSE + neutralizing anti-IL-4
antibody and ifosfamide (F).
Bladders from the saline-treated
group showed normal urothe-
lium with no sign of edema
(ed) or urothelial denuda-
tion (ud). Ifosfamide-injected
bladders exhibited segmental
urothelial denudation, severe
edema with effacement of
the submucosa and occasional
frank hemorrhage. Ifosfamide-
injured bladders exposed to H-
IPSE, IL-4, or MESNA showed
intact urothelium and overall
preserved bladder architecture
with a relative lack of edema.
The protective effect of H-IPSE
was reversed by prior adminis-
tration of neutralizing anti-IL-4
antibody.
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groups receiving ifosfamide showed higher levels of Il-
1b compared with the baseline levels seen in saline-
injected, ifosfamide-naı¨ve mice (dotted line in Fig. 6D).
However, the recombinant IL-4-injected mice exhibited
significantly reduced levels of Il-1b compared with
the ifosfamide-only group. Tnf-a expression levels in
H-IPSE were not significantly reduced relative to
the ifosfamide group but were significantly lower
in H-IPSE groups compared with the group given
neutralizing anti-IL-4 antibody (Fig. 6E). Interestingly,
the expression level of iNOS was significantly reduced
in ifosfamide-exposed mice injected with H-IPSE, its
NLS mutant, or MESNA, whether or not neutralizing
anti-IL-4 antibody injection was coadministered (Fig.
6F). Furthermore, whereas the transcription levels of
Cox-2 and Il-8 were not significantly changed, the level
of gene expression of the macrophage inflammatory
protein Ccl3 was decreased in the H-IPSE groups re-
gardless of NLS mutation or anti-IL-4 antibody treat-
ment (Supplemental Fig. 5).
DISCUSSION
Hemorrhagic cystitis is a form of severe bladder in-
flammation,whichmay result fromvarious infectious and
noninfectious causes (59). Regardless of underlying etiol-
ogy, hemorrhagic cystitis can be associated with signifi-
cant bladder hypersensitivity, including symptoms, such
as urinary frequency, urgency, and bladder pain. Uro-
genital schistosomiasis is a classic infectious cause of
hemorrhagic cystitis, whereas CHC is a major non-
infectious trigger. Hematuria is a cardinal feature of
schistosomiasis-associated hemorrhagic cystitis. It results
from tissue damage as a result of granulomatous in-
filtration of leukocytes in response to antigens continu-
ously released from eggs lodged in the bladder wall
(60). However, only a minority of infected individuals
shows day-to-day hematuria and urinary symptoms (30).
Whereas several other factors, including intensity of in-
fection, are associated with the degree of hematuria, it is
possible that S. hematobium, the helminth that causes uro-
genital schistosomiasis, may be producing host modula-
tory factors to modulate host pathogenesis (61). Indeed,
the interaction between secreted and parasite tegument-
bound molecules and the host-immune response shapes
the evolution of schistosome-associated immunopa-
thogenesis (62). For urogenital schistosomiasis, parasite
factors released from the trapped egg may mediate the
balance between egg passage through the tissue to
complete the life cycle and cause life-threatening path-
ogenesis (which is not in the parasite’s “interests”). IPSE
Figure 5. H-IPSE reduces abnormal voiding behaviors in
ifosfamide-treated mice. Mice were subjected to the voided
spot on paper test to measure their voiding frequency over a 4
h period. As compared with the mice exposed only to
ifosfamide, mice administered H-IPSE and ifosfamide showed
a signiﬁcant reduction in voiding frequency. Administration of
anti-IL-4 mAb seems to reverse the effect of H-IPSE. Plotted
data are from 1 of 2 representative experiments. Horizontal
bars represent means. *P , 0.05, **P , 0.01.
Figure 4. H-IPSE reduces spon-
taneous pain but not evoked
tactile sensitivity in ifosfamide-
treated mice. Mice were admin-
istered recombinant IL-4, H06
H-IPSE, H06 H-IPSE with
neutralizing anti-IL-4 antibody
(a-IL-4), MESNA, or saline be-
fore ifosfamide challenge. A)
Animals were then placed in-
dividually in fresh cages with
new bedding. Mice were evalu-
ated and spontaneous pain
scored (in a blinded fashion).
Higher scores indicate more
pain. B) Mice were subjected
to tactile allodynia assessment
using von Frey monoﬁlaments.
The change in withdrawal threshold is the difference between the 50% withdrawal threshold at baseline and 10-h postifosfamide
injection. As a higher 50% threshold indicates less pain, positive values for changes in withdrawal threshold indicate less pain.
The reduced pain observed in the H-IPSE- and IL-4-treated groups was not signiﬁcant compared with the mice treated with only
ifosfamide. The change in 50% threshold was signiﬁcantly lower in the H-IPSE and H-IPSE NLS mutant groups when
coadministered neutralizing anti-IL-4 antibody. The plotted data are pooled from 3 repeat experiments. Horizontal bars
represent means. *P , 0.05, **P , 0.01, ***P , 0.001.
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is the most abundant secreted protein from S. mansoni
eggs (60).M-IPSE has been shown to bind Igs, ligate IgE
on the surface of basophils and mast cells to induce
these cells to release IL-4 (32–34), and sequester che-
mokines (35) and is an infiltrin that can translocate into
host nuclei to modulate host gene transcription (36–38).
Until now, it was unclear whether these molecular
functions of IPSE could be therapeutically exploited
in inflammation-mediated, clinically relevant dis-
eases. Here, we report the first therapeutic application
of a uropathogen-derivedmolecule inmodels of bladder-
specific pathology, namely chemotherapy-induced bladder
hypersensitivity and hemorrhagic cystitis.
Ifosfamide and cyclophosphamide are nitrogenmustard
alkylating agents used for treatment ofmany cancers (1, 63,
64). However, these agents are associated with a range of
life-threatening side-effects, including hemorrhagic cystitis,
arrhythmias,neuro-andnephrotoxicity,Fanconi syndrome,
and even urothelial cell carcinoma (7, 64, 65). MESNA is
used to prevent CHC but fails to treat hemorrhagic cystitis
after its onset (5, 66, 67). Other options for managing this
debilitating chemotherapy-induced condition, including
use of recombinant IL-4 (10),which has been shown to have
a therapeutic effect in experimental models, and surgical
solutions are often suboptimal and sometimes lead to other
untoward, severe, adverse reactions (17–28). Thus, there is
need for novel therapeutic options for hemorrhagic cystitis.
Inspiration to exploit urogenital parasite-derived, host-
modulatory molecules as potential therapeutics has been
provided by recent advances in the use of gastrointestinal
parasitemodulatoryproteins as therapy for allergic diseases
and autoimmune disorders. There is ongoing research in-
volving administration of crude Trichuris trichiura or hook-
worm ova or worm extracts to treat inflammatory bowel
diseases, such as ulcerative colitis and Crohn’s disease, and
autoimmune disorders, such asmultiple sclerosis and celiac
disease (68–73). In this report,we showthat auropathogenic
parasite-derived molecule (H-IPSE) can ameliorate hemor-
rhagic cystitis, specificallyby reducingbladderhemorrhage,
urothelial denudation, ulceration, and associated pain.
A single intravenous injection of H-IPSE was more
effective than multiple doses of MESNA, the current
Figure 6. H-IPSE restores expression of uroplakin mRNA and reduces proinﬂammatory mediator mRNA expression in the
ifosfamide-injured bladder. Total RNA was puriﬁed from the bladders of mice administered ifosfamide alone or ifosfamide in
addition to the following: saline, recombinant IL-4, H-IPSE, the NLS mutant of H-IPSE, H-IPSE with neutralizing anti-IL-4
antibody (aIL-4), or MESNA. Real-time PCR was then performed to measure transcription of uroplakin genes [Up1a (A) and Up2
(B)] and a tight junction-associated gene [Cldn8 (C)]. After ifosfamide insult, H-IPSE-injected mice showed signiﬁcantly
increased transcript levels of the uroplakin genes vs. mice exposed to ifosfamide alone. Transcription of proinﬂammatory
mediator genes [Il-1b (D), Tnf-a (E), and iNOS (F)] was also assessed. H-IPSE- and MESNA-injected mice showed signiﬁcantly
decreased transcript levels of iNOS compared with mice exposed only to ifosfamide. Ifosfamide-exposed mice, given the NLS
mutant of H-IPSE or H-IPSE in combination with the anti-IL-4 antibody, still had reduced levels of iNOS gene expression
compared with mice given ifosfamide alone. H-IPSE-injected mice also exhibited signiﬁcantly reduced levels of Tnf-a vs. the
group treated with the anti-IL-4 antibody but not Il-1b relative to mice exposed to ifosfamide alone. *P, 0.05, **P, 0.01, ***P,
0.001, ****P , 0.0001.
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standard of care for preventing CHC, in reducing
ifosfamide-induced bladder hemorrhage, as measured by
bladder hemoglobin content. Based on the described func-
tions of M-IPSE, the immediate target of intravenously
administered H-IPSE may be circulating basophils. M-
IPSE binds IgE on the surface of these cells to induce IL-
4 release (32–34). IL-4 induces an anti-inflammatory
phenotype via inhibition of the production and release
of proinflammatory cytokines and mediators, such as
TNF-a, IL-1b, iNOS, and COX-2, and thereby alleviates
inflammation-driven diseases (2, 10–16). Indeed, our data
showed that the ability of H-IPSE to reduce ifosfamide-
triggered bladder hemorrhage relies on an IL-4-dependent
mechanism. The reversal of the effect ofH-IPSEby theNLS
mutant was not statistically significant.
Bladder expression of iNOS was reduced in groups of
ifosfamide-exposed mice receiving the NLS mutant or H-
IPSE, either with or without neutralizing anti-IL-4 anti-
body. It is possible that infiltrating cells andurothelial cells
are a source of iNOS that can be altered by H-IPSE expo-
sure.ThecapacityofH-IPSEto sequesterproinflammatory
chemokines (35) may prevent recruitment and infiltration
of inflammatory cells (74–76). We speculate that the ob-
servedameliorativeeffect,althoughindependentof IL-4-and
NLS-linked mechanisms, may involve other mechanisms
(such as thosemediated by chemokines) inmultipronged or
synergistic interactions.
H-IPSE increased transcription of uroplakin genes in
the ifosfamide-exposed bladders in an IL-4- and NLS-
dependent manner. As expected in this setting, MESNA
also maintained the gene-expression level of uroplakins
(55). Uroplakin gene-expression levels in ifosfamide-
injured bladders were significantly higher in the H-IPSE-
vs. IL-4-treated group. This suggests that H-IPSE induces
higher IL-4 levels than that achieved by administration of
recombinant IL-4 and/or that H-IPSE may have direct or
indirect IL-4-independent effects on urothelial cells that
promote repair responses. The uroplakins are not only
markers of urothelial differentiation but also serve as
barrier function proteins that protect the urothelium and
deeper bladder tissues from damage (57). Not surpris-
ingly, gene expression of all of the uroplakin genes (Up1a,
Up1b,Up2,Up3a,Up3b) reaches a nadir after chemical or
biologic insult (57). Specifically, transcription of these
genes achieves maximal reductions within the first 12 h
after ifosfamide/cyclophosphamide challenge, before the
onset of urothelial regeneration (56, 57). Given that the
bladder-expression level of uroplakin genes in the H-IPSE
groupwas comparable orhigher than the levels seen in the
MESNA-treated group, it is possible that H-IPSE triggers
the same or similar mechanisms of urothelial repair as
MESNA. Indeed, we have found that H-IPSE induces
urothelial cell proliferation in vitro in an NLS-dependent
manner in another study. These findings are consis-
tent with a role for H-IPSE in promoting urothelial re-
generation through IL-4-independent, NLS-dependent
pathways.
Finally, although the observed ameliorative effect of H-
IPSE on hemorrhagic cystitis and associated pathogenesis
is compelling, the exact molecular mechanisms under-
lying the protective effect are still not fully delineated.
For instance, we do not know why H-IPSE decreases
ifosfamide-induced bladder hemorrhage but not edema.
It is also unknown why H-IPSE significantly decreases
spontaneous but not evoked pain in ifosfamide-exposed
mice. Finally, it is unclear how H-IPSE mediates a pro-
found therapeutic effect in the ifosfamide-injured bladders
despite not significantly affecting TNF-a or IL-1b gene
expression. However, the fact that iNOS expression was
decreased inallH-IPSEgroupsmaysuggest that the timing
of the assay may have missed upstream events in the
proinflammatory pathway, in addition to the early onset of
urothelial repair following chemical insult.Ongoingwork is
focusingonmorecomprehensive transcriptionalprofilingof
the IPSE-treated, ifosfamide-injured bladders, in addition to
generating otherH-IPSEmutants thatwill lead to enhanced
efficacy while minimizing potential toxicity. Development
of H-IPSE as a safe therapeutic will need to address the
possibility of histamine release by IgE+ basophil and mast
cell degranulation induced by H-IPSE binding of IgE.
Other potential pitfalls exist in our experimental ap-
proaches. Although we used a well-established clone for
anti-IL-4 antibody-mediated neutralization of this cyto-
kine, this tool does not allow us to link directly H-IPSE-
induced activation of IgE-bearing basophils/mast cells to
IL-4 production.We also currently lack ameans bywhich
to neutralize the chemokine-binding properties ofH-IPSE.
Ongoing efforts are directed toward addressing these
shortcomings. Finally, although NLS is an important me-
diator of IPSE translocation into host cell nuclei, the NLS
mutant of H-IPSE is still capable of reaching nuclei, albeit
at amuch lower efficiency than the wild-type protein (38).
Thus, our observed effects of the NLS mutant may have
beendampened by this residual formof nuclear transport.
In summary,H-IPSE, a uropathogen-derivedmolecule,
alleviates CHC in a mouse model in an IL-4-dependent
fashion.H-IPSEmayprovemoreefficacious thanMESNA,
the current standard of care for prophylaxis against this
devastating complication of chemotherapy. Our H-IPSE
mammalian expression system may poise us for large-
scale protein production that would be necessary for ex-
panded testing of H-IPSE as a therapeutic molecule.
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